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 1 
1. Introduction 2 
Paracetamol (acetyl-para-aminophenol), is a widely used analgesic and antipyretic agent. 3 
Nevertheless, its analgesic mechanism remains elusive and its metabolism is complex. Several studies 4 
on paracetamol metabolites have largely focused on their toxic actions, notably by hepatotoxic 5 
compounds like p-benzoquinone (p-BQ) and N-acetyl-p-benzoquinoneimine (NAPQI). Recently, we 6 
have proposed that a new metabolic pathway, previously described by Högestätt et al. [25], would 7 
be involved in its analgesic action. Paracetamol is metabolized to p-aminophenol, which is itself 8 
metabolized in the brain by the fatty acid amide hydrolase (FAAH) to N-(4-hydroxyphenyl)-9 
5Z,8Z,11Z,14Z-eicosatetraenamide (AM404), which is able to induce analgesia [34]. Interestingly, this 10 
active metabolite is structurally related to lipoaminoacids, a new class of signaling molecules 11 
involved in pain modulation [6,26]. 12 
Members of the lipoaminoacid family, such as anandamide (N-arachidonoyl ethanolamide) 13 
and 2-AG (2-arachidonylglycerol), interact with several targets including cannabinoid [21,47] and 14 
TRPV1 receptors [26,43,56], two main actors involved in pain modulation and in the analgesic action 15 
of paracetamol [34,35]. But interestingly, lipoaminoacids are also able to strongly inhibit T-type 16 
calcium channels, especially the Cav3.2 member, an effect which mediates their analgesic property 17 
[3]. 18 
T-type calcium channels have the exclusive characteristic to be activated by weak 19 
depolarization close to the resting membrane potential conferring them a role of cell excitability 20 
modulator [42]. In the central nervous system, T-type calcium channels participate in epilepsy [5,30], 21 
spontaneous firing [42], slow-wave sleep [31] and pain perception [8,15,51]. Three T-type calcium 22 
channels, Cav3.1, Cav3.2, and Cav3.3, have been described [42]. Among them, Cav3.2 channels are 23 
expressed in small and medium-diameter neurons of the dorsal root ganglion (DRG), in the dorsal 24 
horn superficial laminæ and in several brain structures [50]. In naive and neuropathic animals, we 25 
have shown that Cav3.2 inhibition by antagonists or oligonucleotide antisenses reduced nociceptive 26 
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reactions and hyperalgesia, respectively [8,24]. Finally, Cav3.2 knock-out mice display severe 1 
impairment in pain perception in several pain tests confirming the strong role of this channel in 2 
nociception [15]. 3 
Considering that the AM404 lipoaminoacid was the active metabolite of paracetamol [25] 4 
and that lipoaminoacids were able to inhibit Cav3.2 channels, which modulate nociception and pain 5 
[3], we hypothesized that Cav3.2 channels could be involved in the mechanism of the analgesic 6 
action of paracetamol. In this study, we have investigated the involvement of Cav3.2 channels in this 7 
effect using genetic (Cav3.2 knock-out mice) and pharmacological (Cav3 antagonist, TTA-A2) 8 
strategies in rodents submitted to various nociceptive tests and pathological conditions. 9 
Interestingly, Zygmunt et al. [56] have shown that AM404 is also a TRPV1 agonist. We 10 
previously demonstrated that brain TRPV1 was an essential actor for the analgesic action of 11 
paracetamol [34]. The suspected dual involvement of brain TRPV1 receptor and Cav3.2 channels in 12 
paracetamol action led us to investigate the interaction between these two protagonists. This 13 
potential interaction was studied with a behavioral approach by using genetically modified mice 14 
(Cav3.2 or TRPV1 knock-out mice) and a pharmacological strategy (TTA-A2). We have also used 15 
electrophysiological and calcium imaging technics to investigate the mechanism of the functional 16 
interaction between Cav3.2 channels and TRPV1 receptors. 17 
Overall, our results demonstrate, for the first time, that the supraspinal Cav3.2 T-type 18 
calcium channel works with TRPV1 receptor to support the analgesic action of paracetamol and 19 
consequently highlights them as potential targets for the development of new analgesics. 20 
 21 
2. Materials and methods 22 
2.1 Animals 23 
 Cav3.2 knock-out mice (Cav3.2
-/-
, 20-25 g, male), TRPV1 knock-out mice (TRPV1
-/-
, 20-25 g, 24 
male), originally generated by Chen CC et al. [13] and Caterina et al. [11] respectively, and their wild 25 
type littermates (Cav3.2
+/+
, TRPV1
+/+
, 20-25 g, male) were used. All animals and experiments were 26 
performed with approval by the Committee for Research and Ethical Issues of the IASP and the 27 
Institutional Ethic Committee for animal experiments (CEMEA Auvergne; nr: CE 53 - 12, CE 112 - 12, 28 
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CE 24 - 11, CE 13 - 10). Animals were housed under controlled environmental conditions (21 - 22°C; 1 
55% humidity) and kept under a 12/12h light/dark cycle. Food and water were available ad libitum. 2 
Animals were euthanized by cervical dislocation or CO2. 3 
2.2 Behavioral Studies 4 
 Animals were habituated to the testing environment before baseline testing. The 5 
experimenter and drug administration were blinded to the genotype of the mice and the treatments. 6 
Drug administration was performed a person other than the experimenter. In all experiments, drugs 7 
were orally or subcutaneous administered at 10 ml/kg. 8 
2.3 Actimetry test 9 
 For assessment of locomotor activity, mice were placed in actimetry boxes (Actisystem, 10 
Apelex, Passy, France) and spontaneous motor activity was assessed by determining the number of 11 
crossings of light beams during 15 min. The test was performed 10 min after TTA-A2 or vehicle 12 
administration. 13 
2.4 Intracerebroventricular and intrathecal injections 14 
 Injections were carried out on mice kept under gas anesthesia (isoflurane). The 15 
intracerebroventricular injection was made with a syringe and calibrated needle with a guide so that 16 
the needle diameter was 4 mm. The injection volume was 2 µl per mice. The anesthetized rat was 17 
held in one hand by the pelvic girdle and a 25-gauge X 1-inch needle connected to a 25 µl Hamilton 18 
syringe was inserted into the subarachnoidal space between lumbar vertebrae L5 and L6, until a tail 19 
flick was elicited. The syringe was held in position for few seconds after the injection of a volume of 2 20 
µl per mice. 21 
2.5 Tail and paw immersion tests 22 
 Mice were habituated to handling for three days a week prior to testing. The mouse tail or 23 
paw was immersed in warm water (46°C). Latency to respond to the heat stimulus with a tail or paw 24 
vigorous flexion were measured three times and averaged. The cutoff time was 30 seconds, after 25 
which the tail was removed from the bath regardless of response. Tests were performed 45 minutes 26 
after paracetamol or morphine administration. 27 
2.6 Formalin test 28 
 Mice were allowed to acclimate to a Plexiglas chamber (30 cm x 30 cm x 30 cm) for at least 29 
30 minutes before testing. Formalin (20 µl, 2.5% formalin in saline) was injected into the plantar 30 
surface of one hind paw. Spontaneous pain behavior (licking) was recorded during the two typical 31 
nociceptive phases: from 0 to 5 min (phase I) and from 15 to 40 min (phase II) after formalin injection 32 
as previously described [34]. For AM404 experiments, only phase 1 was studied due to the fast 33 
degradation of AM404 [34]. Paracetamol or morphine administrations were performed 20 minutes 34 
before formalin injection. Capsaicin, AM404 or TTA-A2 were injected 10 minutes before formalin 35 
test. 36 
2.7 Von Frey test 37 
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 Mice were placed in individual compartments on top of a wire surface and allowed to 1 
acclimatize for one hour before testing. Withdrawal thresholds were assessed with the 1.4 g 2 
calibrated von Frey filament (Bioseb, France). The latter was pressed perpendicularly five times 3 
against the mid paw and held for 3 seconds. A positive response was noted if the paw was withdrawn 4 
or licked and a pain response score (from 0 to 5) was determined. Test was performed 45 minutes 5 
after paracetamol or morphine administration or 10 minutes after AM404 or capsaicin injection. 6 
2.8 Monoarthritis Induction 7 
 Five microliters of complete Freund adjuvant (CFA, DIFCO Laboratories, Detroit, USA) [10] 8 
were injected into both sides of the left ankle joint of mice under brief isoflurane anesthesia. 9 
Thermal and mechanical paw thresholds were determined before and 7 days after CFA or vehicle 10 
injection. Baselines for behavioral tests were performed at day 0 and day 7 before experimental 11 
treatments. 12 
2.9 Cell culture and electrophysiological recordings 13 
 Lumbar DRGs with attached roots were dissected from adult male C57BL/6J mice and single 14 
cell suspension was obtained following an enzymatic and mechanical dissociation. Whole cell patch-15 
clamp recordings were performed 3–28 h after plating on medium sized DRG neurons with a 16 
“rosette” phenotype as previously described [24]. For recording calcium current, the extracellular 17 
solution contained (in mM): 2 CaCl2, 100 TEACl, 2 NaCl, 1 MgCl2, 40 Choline Cl, 5 Glucose, 5 4AP (pH 18 
to 7.4 with TEAOH~330 mOsM). Pipettes with a resistance of 1-1.5 Mohm were filled with an internal 19 
solution containing (in mM): 110 CsCl, 3 MgCl2, 10 EGTA, 10 HEPES, 3 Mg-ATP, 0.6 GTP (pH to 7.,4 20 
with CsOH, ~300 mOsM). All recordings were filtered at 5 kHz using an Axopatch 200B amplifier 21 
(Axon instrument). Data was recorded using a pClamp10 (Axon Instrument) and Graphpad Prism 22 
software. Currents were recorded from a holding potential of -75 mV. This maintains the T-type 23 
channels in a partially inactivated state that is often preferentially sensitive to pharmacological 24 
modulations[3,24].  25 
 HEK cells stably expressing the human Cav3.2 sequence were used as previously described 26 
[24] and were transfected with GFP alone or with a mix of TRPV1 and GFP expression plasmids using 27 
JetPEI. Application of capsaicin (1 µM) or AM404 (3 µM) was achieved with a gravity driven WAS-2 28 
perfusion system allowing control of the bath temperature [22]. For AM404 application experiments 29 
were performed at 33-35°C. 30 
2.10 Calcium imaging 31 
 Human embryonic kidney cells, HEK293T, were grown in Dulbecco’s modified Eagle’s medium 32 
(DMEM) containing 10% (v/v) human serum, 2 mM L-glutamine, 2 units/ml penicillin and 2 mg/ml 33 
streptomycin at 37°C in a humidity controlled incubator with 10% CO2. HEK293T cells were 34 
transiently transfected with human TRPV1 using Mirus TransIT-293 (Mirus Corporation; Madison, WI, 35 
USA). To determine if the cells were transfected, capsaicin (1 µM) was used at the end of each 36 
experiment. Cells which did not-respond to capsaicin were used as controls. 37 
 Cells were loaded with 2 µM Fura-2 acetoxymethyl ester for 30 minutes at 37°C. The 38 
intracellular concentration was monitored as the ratio of fluorescence signals measured upon 39 
alternating illumination at 340 and 380 nm, using an MT-10 illumination system and the Cell^M 40 
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software (Olympus). Bath solution contained (in mM) 145 NaCl, 5 KCl, 2 CaCl2, 1.5 MgCl2, 10 HEPES, 1 
10 D-Glucose, pH = 7.4 buffered with NaOH.  2 
 As HEK cells express FAAH, an enzyme [37] which degrades AM404, the experiments of figure 3 
4a have been performed in the presence of a FAAH inhibitor (PMSF, 10 µM). Experiments were 4 
performed at 35-37°C. 5 
2.11 Statistical Analysis 6 
 Data are expressed as mean ± SEM and recorded using SigmaStats 3.5 software. Data were 7 
tested for normality and for equal variance. Multiple measurements were compared by one-way or 8 
two-way ANOVA or by Kruskal-Wallis / Friedman test in the case of data that were not normally 9 
distributed. The post hoc comparisons were performed by the Bonferroni method. Values of P < 0.05 10 
were considered statistically significant. 11 
 12 
3 Results 13 
3.1 Paracetamol fails to produce an analgesic effect in Cav3.2 knock-out mice 14 
 In wild type littermates mice (Cav3.2
+/+
), paracetamol increased the tail withdrawal latency in 15 
the tail immersion test (vehicle: 7.7 ± 0.6 s and paracetamol: 16.0 ± 0.5 s; P < 0.001) (Fig. 1a). 16 
Moreover, paracetamol decreased the paw withdrawal incidence (PWR) in the von Frey test (vehicle: 17 
3.4 ± 0.2 PWR and paracetamol: 2.6 ± 0.2 PWR; P < 0.01) (Fig. 1b) and the licking time of the first 18 
phase (vehicle: 135 ± 11 s and paracetamol: 72 ± 12 s; P < 0.001) and the second phase (vehicle: 241 19 
± 31 s and paracetamol: 61 ± 18 s; P < 0.001) of the formalin test (Fig. 1c). In the same tests 20 
performed in Cav3.2 knock-out mice (Cav3.2
-/-
), paracetamol was not able to modify scores obtained 21 
in control animals (Fig. 1a, b and c). A similar result was obtained in a model of chronic inflammatory 22 
pain induced by a peri-articular injection of Complete Freund Adjuvant in the left hindpaw (CFA 23 
model). Both thermal (vehicle: 3.9 ± 0.23 s and paracetamol: 10.0 ± 0.8 s; P < 0.05) (Fig. 1d) and 24 
mechanical hyperalgesia (vehicle: 4.5 ± 0.2 PWR and paracetamol: 2.1 ± 0.5 PWR; P < 0.01) (Fig. 1e) 25 
were reduced by paracetamol in Cav3.2+/+, while it did not produce any effect in Cav3.2-/- mice. 26 
Deletion of the Cav3.2 channel attenuates reactions to several noxious stimuli (here mainly 27 
heat and mechanical ones) (Fig. 1). Thus, the analgesic effect of paracetamol might be masked by the 28 
Cav3.2
-/-
 mouse hypoalgesic phenotype, introducing a bias in our experiments. We verified whether 29 
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another analgesic drug (morphine, 2 mg/kg s.c.) could be effective in Cav3.2
-/-
 mice. Indeed, 1 
morphine produced a significant analgesic effect in Cav3.2
-/-
 mice in all tests used (Fig. 1) either in 2 
naive mice (tail immersion, von Frey and formalin tests) or in the CFA model (paw immersion and von 3 
Frey tests). 4 
All these findings identify the novel role of Cav3.2 calcium channels in supporting the 5 
analgesic action of paracetamol.  6 
3.2 Supraspinal Cav3.2 calcium channels are needed for paracetamol-induced analgesia 7 
 The first observation was that TTA-A2 (5 µg/mouse), administered by intracerebroventricular 8 
(i.c.v.) route, induced an antinociceptive effect in the first phase (vehicle: 109 ± 8 s and TTA-A2: 72 ± 9 
7 s; P < 0.01) and the second phase (vehicle: 193 ± 18 s and TTA-A2: 93 ± 20 s; P < 0.01) of the 10 
formalin test (Fig. 2a) and in the von Frey test (vehicle: 3.9 ± 0.4 PWR and TTA-A2: 2.6 ± 0.2 PWR; P < 11 
0.01) (Fig. 2b) without inducing a sedative effect (Supplementary Fig. S1).  12 
Secondly, in mice submitted to the formalin (Fig. 2a) or the von Frey (Fig. 2b) tests, co-13 
administration of TTA-A2 (i.c.v.) and paracetamol (200 mg/kg, p.o.) produced an effect not 14 
significantly different compared to the effect of paracetamol or TTA-A2 alone. On the contrary, co-15 
administration of TTA-A2 (i.c.v.) and morphine (1 mg/kg, s.c.) produced a significantly more 16 
pronounced analgesic action than the effect of the same drugs administered alone (Fig. 2a, b).  17 
In parallel, specific action of TTA-A2 on Cav3.2 subtype channels was tested by assessing the 18 
analgesic effect of TTA-A2 i.c.v.-injected in Cav3.2
-/-
 mice in the formalin test. No analgesic action of 19 
TTA-A2 was observed in the first phase (vehicle: 68 ± 9 s and TTA-A2: 56 ± 14 s) nor in the second 20 
phase (vehicle: 106 ± 12 s and TTA-A2: 109 ± 23 s) (Supplementary Fig. S2), confirming the specific 21 
action of this compound on Cav3.2. 22 
A possible involvement of the spinal Cav3.2 calcium channels in paracetamol action has been 23 
investigated by assessing its analgesic action in wild type mice submitted to the formalin test and 24 
treated with TTA-A2. TTA-A2 (5 µg), administered intrathecally (i.t.), induced an analgesic effect in 25 
the first phase (vehicle: 106 ± 12 s and TTA-A2: 65 ± 9 s, P < 0.001) and the second phase (vehicle: 26 
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255 ± 19 s and TTA-A2: 119 ± 29 s, P < 0.001) of the formalin test (Fig. 2c). Interestingly, co-1 
administration of TTA-A2 (5 µg, i.t.) and paracetamol (200 mg/kg, p.o.) induced a significantly higher 2 
analgesic effect than both drugs administered alone. The same result was found with morphine (1 3 
mg/kg, s.c.) and TTA-A2 (5 µg, i.t.) co-administration (Fig. 2c).  4 
All together, these results demonstrate that supraspinal but not spinal Cav3.2 channels are 5 
essential for the analgesic effect of paracetamol. Moreover, they show that specific supraspinal or 6 
spinal inhibition of Cav3.2 calcium channels induce analgesia. 7 
3.3 AM404, the active metabolite of paracetamol, required Cav3.2 channels to mediate its analgesic 8 
effect 9 
 Intracerebroventricular injection of AM404 induced an analgesic effect in Cav3.2
+/+
 mice in 10 
the first phase of the formalin test (vehicle: 85 ± 10 s and AM404: 47 ± 10 s; P < 0.01) (Fig. 3a) and in 11 
the von Frey test, 7 days after peri-articular CFA injection (vehicle: 4.9 ± 0.1 PWR and AM404: 2.8 ± 12 
0.3 PWR; P < 0.01) (Fig. 3b). In the same tests, no analgesic action of i.c.v. administered AM404 was 13 
observed in Cav3.2
-/-
 mice (Fig. 3). 14 
 We further examined in DRG neurons the action of AM404 on Cav3.2 current in a whole-cell 15 
patch clamp method. Contrary to paracetamol and p-aminophenol which did not inhibit Cav3.2 16 
current, AM404 weakly inhibited Cav3.2 current, with a high EC50 = 13.7 µM (Fig. 3c, d), compared to 17 
the antagonist, TTA-A2 (EC50 = 9.0 nM, result not shown).  18 
3.4 TRPV1 receptor and Cav3.2 channel: evidence of a functional relationship 19 
 We first showed that AM404 (10 µM) induced a large intracellular calcium increase 20 
dependent on the TRPV1 receptor (Fig. 4a). AM404 (10 µM) was as efficient as capsaicin (0.5 µM) 21 
and elicited a response in all capsaicin responding cells. In these experimental conditions, we further 22 
demonstrated that p-aminophenol (10 µM) induced a calcium mobilization, albeit much smaller and 23 
slower than AM404 or capsaicin (Fig. 4b). This effect resulted from the action of locally produced 24 
AM404 (transformation of p-aminophenol by HEK expressed FAAH). Indeed effect of p-aminophenol 25 
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application was lost after a treatment with a FAAH inhibitor (PMSF, 10 µM; Fig. 4b). As for direct 1 
application of exogenous AM404, the observed intracellular calcium mobilization depends on TRPV1, 2 
as demonstrated by the use of the TRPV1 antagonist (capsazepin, CAPZ, 20 µM; Fig. 4b, 3 
Supplementary Fig. S3) or the lack of response in cells that were not transfected with the TRPV1 4 
receptor (Fig. 4b). These experiments confirm that AM404 is able to activate TRPV1 receptors and 5 
that p-aminophenol needs to be metabolized by FAAH (into AM404) in order to activate these 6 
receptors. 7 
 We then demonstrated that, in Cav3.2
+/+
 mice, a supraspinal injection (10 µg i.c.v.) of 8 
capsaicin (which needed TRPV1 to induce analgesia, see Supplementary Fig. S4) elicited an analgesic 9 
effect in the first (vehicle: 88 ± 9 s and Cap: 42 ± 13 s, P < 0.01) and second phase (vehicle: 231 ± 24 s 10 
and Cap: 127 ± 30 s, P < 0.05) of the formalin test (Fig. 5a) and in the von Frey test (vehicle: 4.9 ± 0.1 11 
PWR and Cap: 2.5 ± 0.5 PWR, P < 0.01) (Fig. 5b) while it had no effect in Cav3.2
-/-
 mice (Fig. 5a,b). 12 
Conversely, the analgesic effect of i.c.v. administered TTA-A2 was maintained in TRPV1 knock-out 13 
mice (TRPV1-/-) in the first (vehicle: 92 ± 11 s and TTA-A2: 34 ± 7 s, P < 0.001) and second (vehicle: 145 14 
±17 s and TTA-A2: 58 ± 9 s, P < 0.01) phase of the formalin test (Fig. 5c). Taken together, these results 15 
revealed that the analgesic effect induced by an activation of supraspinal TRPV1 receptors needs 16 
Cav3.2 calcium channels and suggests that these two protagonists could be involved sequentially, 17 
Cav3.2 being located downstream of TRPV1 and inhibited after TRPV1 activation, e.g. by AM404. 18 
 Accordingly, we demonstrated, in HEK cells stably expressing recombinant Cav3.2 channels, 19 
that capsaicin, which had a limited and fully reversible inhibitory effect on Cav3.2 channel activity in 20 
the absence of co-expressed TRPV1 (Fig. 5d), potently inhibited Cav3.2 mediated currents when 21 
TRPV1 channels were co-expressed (Fig. 5e). Furthermore, the inhibition was almost irreversible 22 
even upon capsaicin washout. TRPV1 activation by capsaicin led to a linear current/voltage 23 
relationship and augmentation of inward and outward currents at -75 and +75 mV when TRPV1 was 24 
expressed (Supplementary Fig. S5a, b). Pooled experiments showed that capsaicin mediated Cav3.2 25 
inhibition depends on TRPV1 activation (Fig. 5f). In similar experimental conditions, application of 26 
  
Manuscript-KERCKHOVE 
10 
 
AM404 activated TRPV1 channels (Supplementary Fig. S5d). As for native T-type current, AM404 has 1 
also a small inhibitory effect on Cav3.2 (Fig. 5g and Supplementary Fig.S 5c). Corroborating the effect 2 
of capsaicin, AM404-induced TRPV1 activation resulted in a nearly complete inhibition of Cav3.2 3 
activity (Fig. 5h). This latter effect was significantly more pronounced than in HEK cells only 4 
expressing Cav3.2 (Fig. 5i). 5 
4 Discussion 6 
Using different in vitro (patch clamp, calcium imaging) and in vivo (different pain tests and 7 
models) experiments we demonstrated that: 1) supraspinal Cav3.2 channels were involved in 8 
paracetamol analgesic action; 2) supraspinal Cav3.2 channels modulate pain perception and 3) a 9 
functional relationship between TRPV1 receptors and Cav3.2 channels mediates the analgesic action 10 
of paracetamol. 11 
The loss of paracetamol effect in Cav3.2-/- mice regardless of the experimental conditions, 12 
suggests that Cav3.2 channels are needed for the analgesic action of paracetamol not only in acute 13 
nociception but also in inflammatory situations. This involvement might be questioned due to the 14 
reduced response of Cav3.2-/- to noxious stimuli, however, we have demonstrated by using morphine 15 
that an additional analgesia could happen in these mice. Thus the loss of the paracetamol effect can 16 
clearly be linked to Cav3.2 channel deletion and, paracetamol and morphine mediated analgesia can 17 
be clearly distinguished. However these results are not informative in localizing, within the CNS, the 18 
channels involved in the effect of paracetamol. 19 
The site of action of paracetamol is still a matter of debate. Some authors showed a 20 
peripheral action site [19,32,36] while central one was shown by others [7,18,34,35,44,45]. We 21 
previously demonstrated that spinal [35] and brain [34] receptors were involved in the action of 22 
paracetamol in animals and possibly in healthy volunteers too [45]. Cav3.2 channels are widely 23 
located in the body. Notably, Cav3.2 channels are expressed in the spinal cord [37,50] and in 24 
different nuclei in the brain: hypothalamus, thalamus, amygdala, hippocampus, midbrain, and cortex 25 
[50]. Various T-type channel antagonists such as ethosuximide [14,39], mibefradil [33,48], NNC [38] 26 
  
Manuscript-KERCKHOVE 
11 
 
have been used to explore the role of these channels but none of them are highly specific. Recently, 1 
a new class of molecules has been designed, called TTA compounds, which presents  major specificity 2 
for T-type channels [46,52] and a body of evidence placed TTA-A2 as the most specific antagonist of 3 
Cav3.2 subtype channels. We previously demonstrated that its effect on T-type channels was greater 4 
on Cav3.2 than on Cav3.1 and Cav3.3 (EC50 Cav3.1: 100 nM ; Cav3.2: 9 nM ; Cav3.3: 30 nM) [24] and 5 
that its analgesic effect (after systemic administration) was lost in Cav3.2
-/-
 mice [24]. Using i.c.v. 6 
injections, we showed that Cav3.2 inhibition in the CNS mediated analgesic effects. Based on this 7 
data, the loss of an effect of orally administered paracetamol after i.c.v. injection of TTA-A2 8 
demonstrated an involvement of supraspinal Cav3.2 channels but not spinal channels, as shown by 9 
the lack of an occluding effect of i.t. TTA-A2 on paracetamol-induced analgesia. This demonstration 10 
of a supraspinal site of action of paracetamol agrees with our previous work showing the 11 
involvement of supraspinal TRPV1 receptors [34] in paracetamol-induced analgesia. It also agrees 12 
with results obtained in healthy volunteers showing an activation of inhibitory bulbospinal pathways 13 
by paracetamol [44].  14 
Incidentally, it is interesting to note that TTA-A2, administered alone either supraspinally or 15 
spinally, induced analgesia, without affecting locomotion. These results, in line with the analgesia 16 
observed in Cav3.2-/- mice (present and Choi et al. study [15]), confirmed that Cav3.2 calcium 17 
channels are tonically involved in nociception at these two sites to modulate pain. 18 
Regarding the mechanism of the supraspinal involvement of Cav3.2 by paracetamol, previous 19 
results have shown that the central action of paracetamol involves metabolites [25], namely p-20 
aminophenol, transformed in the brain into AM404. AM404, i.c.v.-injected, produced an analgesic 21 
effect in Cav3.2
+/+
 but not in Cav3.2
-/-
 mice in the two tests used. These results demonstrate a 22 
functional link between AM404 and Cav3.2 channels, which has been similarly shown for 23 
lipoaminoacids such as anandamide, some polyunsaturated fatty acids or N-acyl ethanolamide, 24 
which are T-type calcium channel blockers [12,20,49], and for endogenous N-arachidonoyl glycine 25 
(NAGly) a more potent Cav3.2 inhibitor [3]. Interestingly, NAGly promotes an analgesic effect in 26 
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animals [3,26] which is abolished in Cav3.2
-/-
 mice [3], suggesting that an inhibition of Cav3.2 could 1 
support its analgesic effect. The same mechanism could be evoked for AM404. Indeed, AM404 2 
induced an inhibition of native Cav3.2 mediated T-type currents in D-hair DRG neuron subtypes. 3 
However, this inhibition was weak compared to that induced by other lipoaminoacids such as NAGly 4 
[3], which questions the involvement of this direct inhibitory effect in the analgesic action of AM404 5 
observed in vivo.  6 
 A recent work has shown that AM404-induced activation of brain TRPV1 channels was 7 
needed for the analgesic action of paracetamol [34] and p-aminophenol, its first metabolite [4]. 8 
Accordingly, we showed here that p-aminophenol inhibited calcium currents only when FAAH 9 
enzyme and TRPV1 were functional confirming the role of AM404 as an active metabolite and its 10 
activation of TRPV1. We confirmed, using intracellular calcium imaging and a whole cell patch-clamp 11 
recordings, the ability of AM404 to activate TRPV1 (Supplementary fig. S5d) as previously 12 
demonstrated by Zygmunt et al. [56]. The ability of TRPV1 activation to inhibit Cav3.2 channels was 13 
then demonstrated by showing that capsaicin and AM404 (devoid of or inducing a limited direct 14 
inhibitory effect on Cav3.2 channels, respectively) strongly inhibited Cav3.2 currents when HEK cells 15 
were co-transfected with the channels and TRPV1 receptors. This effect was very sensitive since the 16 
basal tonic activity of TRPV1 was also effective in reducing Cav3.2. This effect is reminiscent of 17 
findings in rat sensory neurons, known to express Cav3.2, describing an inhibition of T-type currents 18 
by TRPV1 mediated action [16]. We similarly demonstrated this pathway here by demonstrating the 19 
minimal necessity of the two channels being expressed together, likely located in a close vicinity, to 20 
observe the regulation. Importantly, we further showed that this inhibition can be obtained with 21 
physiological levels of extracellular calcium, in contrary to the previous report from Comunanza et al. 22 
[16], suggesting that this modulation is likely to occur in vivo. The hypothesis stated to explain the 23 
mechanism involved in this modulation is a calcium regulation. Indeed, massive influx of calcium ions 24 
after TRPV1 activation could inhibit Cav3.2 channels through the activation of kinases (for review 25 
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[55]), such as PTK [27], PKA [29,53,54], PKC [9] and ROCK [28] and therefore decrease neuronal 1 
excitability. 2 
 The next step was to characterize this functional link in pain supraspinal modulation. 3 
Intracerebroventricular injection of capsaicin induced analgesia in Cav3.2
+/+
 mice in all the 4 
nociceptive tests. This effect was not observed in Cav3.2
-/-
 mice. Cav3.2 channels are thus needed for 5 
the analgesic effect of the TRPV1 agonists, capsaicin or AM404. However, the reciprocal does not 6 
apply, the analgesic action of i.c.v.-injected TTA-A2 was unchanged in TRPV1-/- mice compared to 7 
littermates. Taken together, these results demonstrate that the agonist of TRPV1 and AM404 induces 8 
analgesia through a supraspinal TRPV1-dependent Cav3.2 current inhibition. That explains why the 9 
antinociceptive effect of paracetamol was inhibited both by both an i.c.v. TRPV1 receptor antagonist 10 
[34] and the Cav3.2 inhibitor TTA-A2. The involvement of supraspinal TRPV1 receptors are in line 11 
with literature showing that activation of brain TRPV1 induces an analgesic effect (for review [40]). 12 
To conclude, we have identified brain Cav3.2 channels as a novel targets for the analgesia 13 
induced by paracetamol. We positioned these channels with two actors previously shown to be 14 
involved in the action of paracetamol: AM404, its bioactive metabolite, and TRPV1 receptors. The 15 
present results led us to complete the sequential events we previously proposed [34,35]
 
to explain 16 
the mechanism of action of paracetamol: metabolism of p-aminophenol (in the liver) and AM404 in 17 
brain (thanks to FAAH) which induces an activation of brain TRPV1 [4] (linked with CB1 receptors) 18 
which in turn induces a Cav3.2 inhibition presently shown to participate in the supraspinal analgesic 19 
effect of paracetamol. Further studies are needed to elucidate the link between brain Cav3.2 20 
inhibition and activation of inhibitory bulbospinal pathways involved in the analgesic effect of 21 
paracetamol [7,35,44]. Finally, we highlighted supraspinal Cav3.2 calcium channels as an important 22 
actor for pain modulation which appears as a promising and interesting target for the treatment of 23 
pain. 24 
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 1 
LEGENDS FOR FIGURES 2 
Figure 1 I Paracetamol fails to induce analgesic effect in Cav3.2 knock-out. The analgesic effect of 3 
paracetamol (PARA, 200 mg/kg per os) was assessed in: (a) tail immersion, (b, e) von Frey, (c) 4 
formalin and (d) paw immersion tests in Cav3.2 knock-out (Cav3.2
-/-
) and their wild-type littermates 5 
(Cav3.2+/+). Morphine (Mor, 2 mg/kg subcutaneous) groups have been used as positive control 6 
groups. In all tests and conditions, paracetamol lacks its analgesic effect in Cav3.2-/- mice. Data are 7 
presented as mean SEM (n = 6–8). *, P < 0.05; compared to vehicle groups. 8 
Figure 2 I Supraspinal Cav3.2 channels are involved in paracetamol analgesic effect. The supraspinal 9 
Cav3.2 calcium channels involvement in paracetamol was investigated specifically by Cav3.2 block in 10 
brain (a, b) and spinal cord (c). TTA-A2 (5 µg/2 µl i.c.v. and 5 µg/5 µl i.t.), paracetamol (PARA; 200 11 
mg/kg p.o.), morphine (Mor; 1 mg/kg s.c.) and co-administrations effect were assessed in: (a, c) 12 
formalin and (b) von Frey (1.4 g) tests. Data are presented as mean SEM (n = 6–8). *, P < 0.05; 13 
compared to vehicle group; †, P < 0.05; compared to TTA-A2 + Mor co-administration group. 14 
Figure 3 I Cav3.2 calcium channels are inhibited by AM404 and essential for AM404-induced 15 
analgesia. AM404 and Cav3.2 calcium channels relationship was assessed by in vitro (whole cell 16 
patch clamp) and in vivo (formalin and von Frey test) approaches. the AM404 analgesic effect (2 µg/2 17 
µl i.c.v.) was assessed in (a) formalin phase 1 and (b) von Frey tests in Cav3.2
-/-
 and Cav3.2
+/+
 mice. (c) 18 
Whole-cell calcium currents recorded from a DRG neurons expressing Cav3.2 channels (D-Hair 19 
neuron) in the absence (control, Ctrl) and in the presence of 1 and 3 µM AM404. Currents were 20 
elicited by a depolarization at -30 mV (200 ms duration) applied every 5 s from -75 mV. (d) Dose-21 
response curve of AM404 in Cav3.2 current (n = 6–8, open diamonds), paracetamol (filled circle) and 22 
p-aminophenol (filled square). Currents were elicited by a depolarization at -30 mV (200 ms duration) 23 
applied every 5 s from -75 mV. Data are presented as mean SEM (n = 6–8). *, P < 0.05; compared to 24 
vehicle groups. 25 
Figure 4 I AM404 and FAAH dependent metabolization of p-aminophenol are TRPV1 activators. (a) 26 
Time course of intracellular calcium elevation in HEK cells transfected with (black traces, n = 18) or 27 
without (gray traces, n = 17) TRPV1 receptors in response to application of capsaicin (0.5 µM) or 28 
AM404 (10 µM). PMSF (10µM) was applied in all experiments to block the degradation of AM404 by 29 
FAAH. Intracellular calcium elevation upon application of 50 µM ATP at the end of the protocol 30 
shows that all the cells (Control and TRPV1 transfected) were effectively loaded with the Fura2 31 
calcium sensitive probe. (b) Application of p-aminophenol evokes Fura2 340/380 ratio in HEK293 32 
cells expressing TRPV1, but not in untransfected cells or in the presence of the FAAH antagonist, 33 
PMSF (10 µM). 34 
Figure 5 I Relationship between Cav3.2 channel and TRPV1 receptor. The capsaicin analgesic effect 35 
(Cap, 10 µg/2 µl i.c.v.) was assessed in (a) formalin (2.5%) and (b) von Frey tests in Cav3.2
-/-
 and 36 
Cav3.2
+/+
 mice. TTA-A2 analgesic effect (5 µg/2 µl i.c.v.) was assessed in (c) formalin test in TRPV1 37 
knock-out mice (TRPV1
-/-
) and their wild type littermates (TRPV1
+/+
). (d) Representative Cav3.2 38 
current traces evoked by 200 ms depolarization ramps from -75mV to +75mV, under control 39 
conditions (black trace) and during the washout of 1 µM capsaicin (gray trace) on a typical HEK cell 40 
expressing Cav3.2 alone. Evolution of the maximal inward current evoked by the depolarizing ramp 41 
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during the time course of the experiment is plotted on the bottom part. The time points labeled as 1 
(1) and (2) correspond to the upper control and wash traces respectively. (e) Same representation as 2 
in (d) for a typical HEK cell expressing Cav3.2 and TRPV1. Note that in this case the Cav3.2 mediated 3 
current is nearly abolished after capsaicin stimulation of TRPV1. (f) Mean Cav3.2 inhibition mediated 4 
after 1 µM capsaicin application when TRPV1 is coexpressed (black bar) or not (open bar). Data are 5 
presented as mean SEM (n = 6–8). (g,h) Evolution of the maximal inward current evoked by the 6 
depolarizing ramp during the time course of a similar experiment as in (d,e) but using AM404. (i) 7 
Mean Cav3.2 inhibition mediated after 3 µM AM404 application when TRPV1 is coexpressed (black 8 
bar) or not (open bar). Data are presented as mean SEM (n = 6–8). *, P < 0.05; compared to vehicle 9 
groups (behavior) or with or without TRPV1 (electrophysiology). 10 
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Summary 1 
 2 
The supraspinal Cav3.2 calcium channels are involved in analgesic effect of paracetamol, 3 
through their inhibition following the activation of supraspinal TRPV1 receptors by AM404. 4 
5 
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ABSTRACT 1 
To exert analgesic action, paracetamol requires complex metabolization to produce a brain specific 2 
lipoaminoacid compound, AM404, which targets central TRPV1 receptors. Lipoaminoacids are also 3 
known to induce analgesia through T-type channel inhibition (Cav3.2). In this study we show that the 4 
antinociceptive effect of paracetamol is lost in mice when supraspinal Cav3.2 channels are inhibited. 5 
Therefore, we hypothesized a relationship between supraspinal Cav3.2 and TRPV1, via AM404, which 6 
mediates the analgesic effect of paracetamol. AM404 is able to activate TRPV1 and weakly inhibits 7 
Cav3.2. Interestingly, activation of TRPV1 induces a strong inhibition of Cav3.2 current. Supporting 8 
this, intracerebroventricular administration of AM404 or capsaicin produces antinociception that is 9 
lost in Cav3.2
−/−
 mice. Our study, for the first time, (1) provides a molecular mechanism for the 10 
supraspinal antinociceptive effect of paracetamol, (2) identifies the relationship between TRPV1 and 11 
Cav3.2 and (3) discloses supraspinal Cav3.2 inhibition as a potential pharmacological strategy to 12 
alleviate pain. 13 
 14 
